2014
An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation
Chaloupka FJ, Warner KE, Acemoğlu D, Gruber J, Laux F, Max W, Newhouse J, Schelling T, Sindelar J. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation. Tobacco Control 2014, 24: 112. PMID: 25550419, PMCID: PMC4345832, DOI: 10.1136/tobaccocontrol-2014-052022.Peer-Reviewed Original ResearchConceptsEconomic impact analysisSound economic analysisNet economic benefitsImpact analysisProminent economistsSignificant regulatory actionsEconomic analysisDrug Administration's regulatory authorityNet benefitEconomic benefitsTobacco productsGraphic warning labelsRegulatory authoritiesLabel regulationsCostTobacco product regulationRegulatory actionProduct regulationEconomistsAuthoritiesBenefitsFuture analysesRulesControl ActJurisdictions
2007
Willingness to pay for drug rehabilitation: Implications for cost recovery
Bishai D, Sindelar J, Ricketts EP, Huettner S, Cornelius L, Lloyd JJ, Havens JR, Latkin CA, Strathdee SA. Willingness to pay for drug rehabilitation: Implications for cost recovery. Journal Of Health Economics 2007, 27: 959-972. PMID: 18207264, PMCID: PMC2601723, DOI: 10.1016/j.jhealeco.2007.11.007.Peer-Reviewed Original ResearchCost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysis
2003
Economic Costs of Influenza-Related Work Absenteeism
Akazawa M, Sindelar JL, Paltiel AD. Economic Costs of Influenza-Related Work Absenteeism. Value In Health 2003, 6: 107-115. PMID: 12641861, DOI: 10.1046/j.1524-4733.2003.00209.x.Peer-Reviewed Original ResearchConceptsNet benefitEconomic costsMedical Expenditure Panel Survey Household ComponentMean productivity costsAverage work lossDollar termsUS dollarsEmployment dataProductivity impactEconomic attractivenessNumber of workdaysWorking-age peopleHousehold ComponentProductivity costsWorker productivityWorker absenteeismEmployment factorsSimple frameworkInfluenza-like illnessDecision analysisReduced absenteeismCostBaseline analysisInfluenza vaccinationTerms of absence
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates
2000
Can the Treatment Services Review be used to estimate the costs of addiction and ancillary services?
French M, Roebuck M, McLellan A, Sindelar J. Can the Treatment Services Review be used to estimate the costs of addiction and ancillary services? Journal Of Substance Abuse 2000, 12: 341-361. PMID: 11452838, DOI: 10.1016/s0899-3289(01)00058-x.Peer-Reviewed Original ResearchConceptsUnit cost estimatesCosts of addictionCost estimatesTreatment Services ReviewEconomic evaluation purposesAncillary servicesEconomic cost analysisBenefit-cost ratioCost analysis methodCost analysisComprehensive cost analysisFinancial informationEconomic costsService utilization informationCost analysis toolEstimation purposesService delivery unitsCostUtilization informationFuture evaluation studiesService measuresEstimatesPolicymakersServicesEvaluation study
1996
Employment, unemployment, and problem drinking
Mullahy J, Sindelar J. Employment, unemployment, and problem drinking. Journal Of Health Economics 1996, 15: 409-434. PMID: 10164037, DOI: 10.1016/s0167-6296(96)00489-4.Peer-Reviewed Original Research
1994
Alcoholism and income: the role of indirect effects.
Mullahy J, Sindelar JL. Alcoholism and income: the role of indirect effects. Milbank Quarterly 1994, 72: 359-75. PMID: 8007903, DOI: 10.2307/3350300.Peer-Reviewed Original Research